Skip to content

Free cash flow at other companies

Pfizer logo
PfizerPFE
$2.18B+23.0%
Amgen logo
AmgenAMGN
$1.48B+50.7%
Organon logo
OrganonOGN
$188M+337%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$89.27M-12.1%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$50.04M+125%
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%

Valuation

See full
Market cap$3.28B+57.5%
Enterprise value$3.36B+57.0%
P/S7.9×-1.9×

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Calculated from Arcutis Biotherapeutics, Inc.’s reported figures.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s free cash flow?
Arcutis Biotherapeutics, Inc. (ARQT) reported free cash flow of $2.24M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s free cash flow changed year-over-year?
Arcutis Biotherapeutics, Inc.'s free cash flow increased by 107.2% year-over-year, from -$30.99M to $2.24M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s free cash flow?
Over 3 years (2021 to 2024), Arcutis Biotherapeutics, Inc.'s free cash flow has grown at a -13.8% compound annual growth rate (CAGR), from -$175.62M to -$112.3M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.